Literature DB >> 1347773

The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-erbB-2 oncoprotein in human pancreatic cancer.

Y Yamanaka1.   

Abstract

The expressions of epidermal growth factors (EGF), epidermal growth factor receptors (EGFR), and the c-erbB-2 oncoprotein were immunohistochemically examined in 25 cases of human pancreatic carcinoma and epineoplastic pancreatitis and in 10 non-cancerous/non-inflammatory pancreatic tissues. The positive rates of EGF, EGFR, and the c-erbB-2 oncoprotein in cancer tissues were 72%, 36%, and 28%, respectively. EGF was stained mainly in the cytoplasm and partly on the surfaces of the cancer cells. EGFR and the c-erbB-2 oncoprotein were stained mainly on the surfaces of the cancer cells and partly in the cytoplasm. The expressions of these 3 products correlated significantly with tumor invasion into the anterior and posterior areas surrounding the pancreas. In the EGF, EGFR, and c-erbB-2 positive cancer tissues, some stromal cells, that is fibroblasts and endothelial cells, were also positive. In the adjacent pancreatic tissues with inflammation, these products were noted in some ductal cells, acinar cells, fibroblasts and endothelial cells. No distinct staining was detected in non-cancerous/non-inflammatory tissues. The survival period for patients who tested positive for these three proteins was statistically shorter than for those who tested negative. These results suggest that the coexpression of EGF and EGFR and the expression of the c-erbB-2 oncoprotein are related to the existence of the invasion of human pancreatic cancer. Furthermore, an immunohistochemical examination of these three products is useful in forming a prognosis for pancreatic cancer patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347773     DOI: 10.1272/jnms1923.59.51

Source DB:  PubMed          Journal:  Nihon Ika Daigaku Zasshi        ISSN: 0048-0444


  9 in total

1.  Monoclonal antibody (MAB) in patients with advanced cancer.

Authors:  Hyung L Kim; Allan J Pantuck; Nazy Zomorodian; Arie S Belldegrun
Journal:  Curr Urol Rep       Date:  2003-02       Impact factor: 3.092

Review 2.  Selective Raf inhibition in cancer therapy.

Authors:  Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

Review 3.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

4.  Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.

Authors:  Paolo Piacentini; Massimo Donadelli; Chiara Costanzo; Patrick S Moore; Marta Palmieri; Aldo Scarpa
Journal:  Virchows Arch       Date:  2006-03-28       Impact factor: 4.064

5.  Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma.

Authors:  Amit Mahipal; Mary J Mcdonald; Agnieszka Witkiewicz; Brian I Carr
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

Review 6.  Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities.

Authors:  Xiaoxin Ren; Yixian Li; Christopher Nishimura; Xingxing Zang
Journal:  Genes Dis       Date:  2021-09-20

7.  Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival.

Authors:  S Lei; H E Appert; B Nakata; D R Domenico; K Kim; J M Howard
Journal:  Int J Pancreatol       Date:  1995-02

8.  Keratinocyte growth factor induces matrix metalloproteinase-9 expression and correlates with venous invasion in pancreatic cancer.

Authors:  Kazumitsu Cho; Yoko Matsuda; Junji Ueda; Eiji Uchida; Zenya Naito; Toshiyuki Ishiwata
Journal:  Int J Oncol       Date:  2011-12-06       Impact factor: 5.650

9.  Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery.

Authors:  Susanna W L de Geus; Leonora S F Boogerd; Rutger-Jan Swijnenburg; J Sven D Mieog; Willemieke S F J Tummers; Hendrica A J M Prevoo; Cornelis F M Sier; Hans Morreau; Bert A Bonsing; Cornelis J H van de Velde; Alexander L Vahrmeijer; Peter J K Kuppen
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.